• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4618911)   Today's Articles (2442)   Subscriber (49403)
For: Kay J, Feagan BG, Guirguis MS, Keystone EC, Klein AV, Lubiniecki AS, Mould DR, Nyarko KA, Ridgway AA, Trudeau ME, Wang J. Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012. Biologicals 2012;40:517-27. [DOI: 10.1016/j.biologicals.2012.09.010] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2012] [Revised: 09/25/2012] [Accepted: 09/27/2012] [Indexed: 11/23/2022]  Open
Number Cited by Other Article(s)
1
Kugener VF, Freedland ES, Maynard KI, Aimer O, Webster PS, Salas M, Gossell-Williams M. Enhancing Pharmacovigilance from the US Experience: Current Practices and Future Opportunities. Drug Saf 2021;44:843-852. [PMID: 33993430 PMCID: PMC8123099 DOI: 10.1007/s40264-021-01078-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/29/2021] [Indexed: 12/17/2022]
2
Esteban E, Bustos RH, García JC, Jáuregui E. Biosimilars: An Approach to some Current Worldwide Regulation Frameworks. ACTA ACUST UNITED AC 2019;14:16-40. [DOI: 10.2174/1574884713666181025142928] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2018] [Revised: 10/12/2018] [Accepted: 10/19/2018] [Indexed: 12/26/2022]
3
Nabhan C, Valley A, Feinberg BA. Barriers to Oncology Biosimilars Uptake in the United States. Oncologist 2018;23:1261-1265. [PMID: 30049886 PMCID: PMC6291332 DOI: 10.1634/theoncologist.2018-0066] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2018] [Revised: 05/17/2018] [Accepted: 05/17/2018] [Indexed: 01/13/2023]  Open
4
Kay J, Schoels MM, Dörner T, Emery P, Kvien TK, Smolen JS, Breedveld FC. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis 2018;77:165-174. [PMID: 28866648 DOI: 10.1136/annrheumdis-2017-211937] [Citation(s) in RCA: 138] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2017] [Revised: 07/20/2017] [Accepted: 08/12/2017] [Indexed: 12/30/2022]
5
Biologics and biosimilars: a legal perspective from Canada. Pharm Pat Anal 2016;5:79-81. [PMID: 26891094 DOI: 10.4155/ppa-2016-0001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
6
Use of Biosimilars in Paediatric Inflammatory Bowel Disease: A Position Statement of the ESPGHAN Paediatric IBD Porto Group. J Pediatr Gastroenterol Nutr 2015;61:503-8. [PMID: 26154031 DOI: 10.1097/mpg.0000000000000903] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
7
Abad Hernández MÁ, Andreu JL, Caracuel Ruiz MÁ, Belmonte Serrano MÁ, Díaz-González F, Moreno Muelas JV. Documento de posicionamiento de la Sociedad Española de Reumatología sobre fármacos biosimilares. ACTA ACUST UNITED AC 2015;11:269-78. [DOI: 10.1016/j.reuma.2015.03.009] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2015] [Accepted: 03/06/2015] [Indexed: 02/09/2023]
8
Introduction and commentary: Biosimilars—clinical trial and safety considerations. Semin Arthritis Rheum 2015;44:S1. [DOI: 10.1016/j.semarthrit.2014.10.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2014] [Accepted: 10/24/2014] [Indexed: 11/18/2022]
9
Bocquet F, Paubel P, Fusier I, Cordonnier AL, Sinègre M, Le Pen C. Biosimilar versus patented erythropoietins: learning from 5 years of European and Japanese experience. APPLIED HEALTH ECONOMICS AND HEALTH POLICY 2015;13:47-59. [PMID: 25189295 DOI: 10.1007/s40258-014-0125-6] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
10
Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists. Clin Rheumatol 2015;34:1427-33. [DOI: 10.1007/s10067-014-2835-4] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2014] [Accepted: 11/20/2014] [Indexed: 12/30/2022]
11
Ryan AM. Frontiers in nonclinical drug development: biosimilars. Vet Pathol 2014;52:419-26. [PMID: 25161206 DOI: 10.1177/0300985814547282] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
12
Scott BJ, Klein AV, Wang J. Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation. J Clin Pharmacol 2014;55 Suppl 3:S123-32. [PMID: 24965228 DOI: 10.1002/jcph.339] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2014] [Accepted: 06/01/2014] [Indexed: 12/21/2022]
13
Feagan BG, Choquette D, Ghosh S, Gladman DD, Ho V, Meibohm B, Zou G, Xu Z, Shankar G, Sealey DC, Russell AS. The challenge of indication extrapolation for infliximab biosimilars. Biologicals 2014;42:177-83. [PMID: 24962198 DOI: 10.1016/j.biologicals.2014.05.005] [Citation(s) in RCA: 94] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2014] [Revised: 05/22/2014] [Accepted: 05/30/2014] [Indexed: 12/14/2022]  Open
14
Devlin SM, Bressler B, Bernstein CN, Fedorak RN, Bitton A, Singh H, Feagan BG. Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics. CANADIAN JOURNAL OF GASTROENTEROLOGY = JOURNAL CANADIEN DE GASTROENTEROLOGIE 2013;27:567-71. [PMID: 24106727 PMCID: PMC3805336 DOI: 10.1155/2013/327120] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA